Table 2. Number of events, follow-up and incidence rate for the study mediators and outcomes between PPI and H2RA users (grace period = 90 days).
| Measures | Before propensity score matching (N = 59,322) | After 1:1 propensity score matching (N = 7,448) | ||
|---|---|---|---|---|
| H2RAs | PPIs | H2RAs | PPIs | |
| Total number of participants (%) | 3,933 (6.63) | 55,389 (93.36) | 3,928 (50.00) | 3,928 (50.00) |
| Total follow-up (person-years) | ||||
| CVD | 2,790.16 | 25,720.23 | 2,783.98 | 1,849.94 |
| IS | 2,376.46 | 20,596.56 | 2,370.29 | 1,461.47 |
| PVD | 2,293.89 | 18,529.93 | 2,287.72 | 1,322.12 |
| Median follow-up years (IQR) | ||||
| CVD | 0.25 (0–0.25) | 0.25 (0–0.25) | 0.25 (0–0.25) | 0.25 (0–0.25) |
| IS | 0.25 (0–0.25) | 0.25 (0–0.25) | 0.25 (0–0.25) | 0.25 (0–0.25) |
| PVD | 0.25 (0–0.25) | 0.25 (0–0.25) | 0.25 (0–0.25) | 0.25 (0–0.25) |
| No. of participants with events | ||||
| CVD | 151 | 2,130 | 151 | 163 |
| IS | 29 | 722 | 29 | 48 |
| PVD | 2 | 165 | 2 | 13 |
| Incidence rate per 100 person-years (95% CI) | ||||
| CVD | 5.41 (4.58–6.35) | 8.28 (7.93–8.61) | 5.42 (4.59–6.36) | 8.81 (7.51–10.27) |
| IS | 1.22 (0.82–1.75) | 3.51 (3.25–3.77) | 1.223 (0.82–1.76) | 3.28 (2.42–4.36) |
| PVD | 0.09 (0.01–0.32) | 0.89 (0.76–1.04) | 0.09 (0.01–0.32) | 0.98 (0.52–1.68) |
Note:
PPIs, proton pump inhibitors; H2RAs, histamine-2-receptor antagonists; IQR, interquartile range; CVD, cardiovascular disease; IS, ischemic stroke; PVD, peripheral vascular disease.